Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Julia Marie Eastland
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 106
- Beta
- 1.86
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -8.57
Financials
Revenue
$0.00-100.0%Net Income
$-77.64MEBITDA
$-77.23MFree Cash Flow
$-70.23MEPS (diluted)
$-1.10Shares Outstanding (diluted)
70.26M+289.1%Operating Expenses
$82.25MCash & Debt
$174.61MRevenue by Segment (annual)
$67.42MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-137.06M | $-1.91 |
| 2024 | $67.42M | $-165.84M | $-2.33 |
| 2023 | $0.00 | $-292.19M | $-4.47 |
| 2022 | $0.00 | $-236.81M | $-4.48 |
| 2021 | $0.00 | $-158.72M | $-3.72 |
| 2020 | $0.00 | $-117.84M | $-2.87 |
| 2019 | $0.00 | $-45.66M | $-1.29 |
| 2018 | $14.0K | $-21.07M | $-1.17 |
Valuation
ZNTLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
103+29.17%Social Signal Score
Mentions (6)
- Newsbenzinga.com·19d ago·Neutral
This Small Biotech's Cancer Drug Could Reach $1.3 Billion In Peak Sales Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) received a bullish initiation from William Blair on Tuesday, which sees a potential blockbuster opportunity for the biotech company's lead cancer drug, azenosertib.
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences:
View source ↗ - Newsseekingalpha.com·35d ago·Positive
Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib Zentalis Pharmaceuticals, Inc. earns a cautious Buy rating, driven by azenosertib's potential in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). DENALI and ASPENOVA trials target accelerated and full FDA approval, with pivotal data expected in H1 '27 as a major catalyst. Recent $93m capital raise extends cash runway into 2028, supporting regulatory milestones and mitigating near-term funding risk.
View source ↗ - Newsglobenewswire.com·49d ago·Negative
…, Including Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced that it has closed its previously announced underwritten public offering of 26…
View source ↗ - Newsglobenewswire.com·53d ago·Negative
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the pricing of an underwritten public offering of 23,000,000 shares of its common s…
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $-0.58 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.59 vs $-0.49miss
- Tue, May 12$-0.50 vs $-0.49miss
- Thu, Mar 26$-0.49 vs $-0.41miss
- Mon, Nov 10$-0.37 vs $-0.49beat
- Wed, Aug 6$-0.37 vs $-0.56beat
- Wed, May 14$-0.67 vs $-0.67beat
Estimates and results for ZNTL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ZNTL officers and directors.
- Bought
- $23.4m
- Sold
- $10.7m
9 trades
23 trades
- Walters Groupbought
- Vultaggio Vincentsold
- Bruns Ingmarsold
- Vultaggio Vincentsold
- Eastland Julia Mariesold
- Bruns Ingmarsold
- Vultaggio Vincentsold
- Eastland Julia Mariesold
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ZNTL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.